钇90微球管理专家共识  

Experts consensus on management of yttrium-90 microspheres

作　　者：中国抗癌协会肿瘤介入学专业委员会 国家卫生健康委能力建设和继续教育中心介入医学专家委员会 宋莉[1] 邹英华[1] Chinese Society of Interventional Oncology,Chinese Anti-Cancer Association;Expert Committee of Interventional Medicine,National Health Commission Capacity Building and Continuing Education Cente;SONG Li;ZOU Yinghua(Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing 100034, China)

机构地区：[1]北京大学第一医院介入血管外科,北京100034

出　　处：《中国介入影像与治疗学》2021年第6期321-325,共5页Chinese Journal of Interventional Imaging and Therapy

摘　　要：我国肝癌患病人数居于世界首位,严重威胁人民生命健康。钇90微球在国外已应用近20年,对原发性肝癌以及转移性肝癌疗效确切、不良反应少。值此钇90即将于国内上市之际,为指导相关临床医护人员更规范地使用钇90微球,国内从事恶性肿瘤治疗的介入放射学专家就钇90微球治疗肝恶性肿瘤的相关管理办法进行充分深入讨论后达成本共识。The amount of patients suffering from hepatocellular carcinoma(HCC)in China ranks the first in the world,posing a serious threat to the health and fitness.Yttrium 90 microspheres have been used abroad for nearly 20 years,which have definite curative effect in primary liver cancer and metastatic liver cancer with few side effects.On the occasion of yttrium 90 going to be launched in China,in order to guide relevant clinical staff to use yttrium 90 microspheres in a more standardized manner,domestic interventional radiologists engaged in treatment of malignant tumors conducted a discussion on the hospital management of yttrium 90 microspheres for treatment of liver malignant tumors and reached this experts consensus.

关 键 词：肝肿瘤 介入治疗 钇90微球 院内管理 专家共识 

分 类 号：R735.7[医药卫生—肿瘤] R815[医药卫生—临床医学]